For example, CXCR2-modified GPC3-CART had improved trafficking in a hepatocellular carcinoma model (92), while a CXCR1/2-modified CD70-CART enhanced CART trafficking and efficacy in murine GBM, ovarian cancer and pancreatic cancer models (93). Here, GPC3 is linked to hepatocellular carcinoma.